Assessment of Quality of Life in Patients Under Go Neangioplasty and Takin Gticagrelor: A Prospective Observational Study

Abstract

Acute Coronary Syndrome encompasses life threatening conditions including STEMI, NSTE, NSTEMI, and UA. Ticagrelor, an antiplatelet drug, reduces cardiac events but increases bleeding risk. DAPT with ticagrelor and aspirin is recommended post-PCI, with the duration determined by individual factors. Comprehensive prospective studies are essential to assess ticagrelor's real-world effectiveness and impact on patients' quality of life